Send to

Choose Destination
Pharmacogenomics. 2015;16(7):755-67. doi: 10.2217/pgs.15.21. Epub 2015 May 12.

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.

Author information

1Faculty of Pharmacy, Université de Montréal, 2900 Boulevard Edouard-Montpetit, Montreal QC H3T 1J4, Canada.
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Center, Montreal, Canada.
3Faculty of Medicine, Université de Montréal, Montreal, Canada.
4Montreal Heart Institute, Research Center, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada.


Pharmacogenomic markers in the HLA coding genes have been associated with drug hypersensitivity of multiple drugs, including allopurinol. In this systematic review, we summarize the pharmacogenomic evidence available regarding allopurinol-induced cutaneous adverse drug reactions (cADRs). We found that the HLA-B*5801 allele was significantly associated with the risk of severe cADRs in the Han Chinese, Korean, Thai, Japanese and European populations. The association between less severe cADRs and HLA-B*5801 was less consistent. All SNPs identified in genome-wide association studies of common variants were also located in or nearby HLA-B*5801. Future studies should focus on more common but less severe allopurinol-induced cADRs, as well as the potential role of rare variants as predictors of these cADRs.


HLA; Stevens–Johnson syndrome; adverse reaction; allopurinol; drug-induced hypersensitivity syndrome; pharmacogenomics; rash; safety; toxic epidermal necrolysis

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center